Houston's health tech and startup ecosystem has some recent news to catch up on. Photo via Getty Images

Houston startup founders have been moving and shaking in the local innovation ecosystem — from growing their executive boards to raising fresh grant funding.

In this roundup of Houston startup and innovation news, a startup opens a crowdfunding round, a Houston hospital system taps into new technology, and more.

Coya Therapeutics names new president and chief medical officer

Fred Grossman will assume his new role next week. Photo via LinkedIn

Coya Therapeutics Inc. (NASDAQ: COYA), a revolutionary biotech company based in Houston, named Dr. Fred Grossman as president and chief medical officer. The clinical-stage company, which has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again, announced the closing of its $15.25 million IPO in January.

According to the company, Dr. Grossman's position, which was held by Dr. Adrian Hepner, is effective July 17.

“We are grateful for Dr. Hepner’s leadership and excellence in positioning Coya and look forward to having him continue to collaborate with the company in moving our assets forward," Howard H. Berman, CEO of Coya, says in a news release. "We also welcome Dr. Grossman, who brings decades of clinical development experience and successful execution."

Dr. Grossman has held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, Sunovion, Glenmark Pharmaceuticals, and Mesoblast Inc. (NASDAQ: MESO), developing allogeneic cellular therapies for inflammatory diseases.

CellChorus receives another SBIR grant

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured additional funding. Photo via Getty Images

Fresh off a $2.3 million grant last month, Houston-based CellChorus, a single-cell analysis company, has another grant to celebrate.

The U.S. National Science Foundation has awarded CellChorus a Small Business Innovation Research (SBIR) grant to advance development of its Time-lapse Imaging Microscopy In Nanowell Grids, known as TIMING. The funding will be used to develop novel microscale arrays to support scaling dynamic single-cell analysis.

“This funding will further development of novel arrays to build on the success of our early access laboratory based in Houston,” says Mohsen Fathi, head of technology at CellChorus, in a press release. “This project will support scaling the only platform that can evaluate migration, contact dynamics, killing, survival, subcellular activity, and biomolecule secretion for the same individual cell over time and in high throughput to improve development and delivery of novel therapies.”

According to the release, the company is receiving more than $274,000 as a part of the grant, but CellChorus has the potential of receiving up to $2 million from the second phase.

“This award builds on our recent funding from the National Institute of General Medical Sciences to advance development of a dedicated instrument platform for TIMING,” says Daniel Meyer, CEO of CellChorus, in the release.

Memorial Hermann partners with TMC-backed virtual OB-GYN care

Two Houston-area hospitals now have access to this digital health startup's platform. Photo via Getty Images

The Memorial Hermann Health System has entered into a partnership with Washington, D.C.-based Babyscripts, a virtual care platform for managing obstetrics. The company is backed by the Texas Medical Center's venture fund and has existing ties to the city.

"Memorial Hermann strives to make Greater Houston a place where every woman's pregnancy, delivery and postpartum experience is successful and safe. This innovative partnership is a continuation of that commitment," says Dr. Victoria Regan, vice president of Women's and Children's Services at Memorial Hermann, in a news release.

Now, Memorial Hermann patients will be able to access Babyscripts myJourney, an app that delivers educational content, email campaigns, satisfaction surveys, appointment reminders, and more. The first two hospitals to receive access are Memorial Hermann Memorial City Medical Center and Memorial Hermann The Woodlands Medical Center, with plans to expand the program.

"The ability to access adequate prenatal and postpartum care is one of the largest predictors of maternal and infant health outcomes," says Anish Sebastian, CEO and co-founder of Babyscripts in the release. "With Babyscripts, Memorial Hermann is able to streamline the maternal health experience across their system, adding opportunities for access and providing consistent, high-quality pregnancy care to all patients, regardless of race, income, geography or risk."

Earn Your Freedom launches crowdfunding campaign with Houston nonprofit's support

Earn Your Freedom is looking for financial support from its community. Photo via houston.impacthub.net

Earn Your Freedom, a Houston startup that's gamifying personal finance education, has launched its first crowdfunding campaign in partnership with Impact Hub Houston.

The goal for EYF is to raise $100,000 to support its gaming programs with local schools. Impact Hub Houston is the fiscal sponsor for the raise, which is officially live and open for contributions.

The innovative and interactive web and mobile video game, which officially launched earlier this year to celebrate Financial Literacy Month, was designed to help kids build a strong foundation in money management, economics and investment in a fun and engaging way. It features challenges and real-world scenarios such as renting a first apartment, opening a first bank account, budgeting at the grocery store, buying stocks and index funds and renting or buying real estate.

“We envision a society where financial literacy is accessible to all, and where individuals are enabled with the tools to take control of their financial futures," says Keely McEnery, EYF co-founder and COO, in a press release. "We are bridging the gap between education and application, stepping in before the real-world consequences take place.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

European spacecraft developer expands to Houston with U.S. business, new lab

houston hq

European aerospace manufacturer The Exploration Company has established its first U.S. entity and named Space City as its headquarters.

The company announced earlier this month that it has launched TEC Federal to support U.S. government customers and agencies, and to scale The Exploration Company's engineering operations in the country.

Mark Kirasich serves as president of TEC Federal. Kirasich most recently served as the senior director of human spaceflight at Blue Origin after a nearly 40-year career at NASA.

The Exploration Company is developing the reusable Nyx space vehicle. Nyx is designed to take off from any heavy launcher in the world. It will then dock at space stations, retrieve up to 3,000 kilograms of cargo, splash down and return the cargo to Earth. The company aims to make Nyx fully reusable for up to 10 missions, making it a more affordable and sustainable option for aerospace missions.

The Exploration Company completed a successful drop test of the spacecraft in May in the Mojave Desert. The company says Nyx is slated to perform its first flight demonstration in 2028.

In addition to launching the Houston business, The Exploration Company also opened its new Rapid Innovation Lab near Houston's NASA Johnson Space Center on Space Park Drive.

The Exploration Company opened its Rapid Innovation Lab earlier this month. Photo via LinkedIn

The Rapid Innovation Lab features a full-scale mockup of the future Nyx crew capsule as well as ongoing development and testing of the Nyx cargo capsule, according to the company.

The Exploration Company says the new lab will allow its engineers, designers, and operators to prototype and test crew interfaces. It will also support partnerships with NASA personnel and astronauts.

“Houston gives us direct access to the people and expertise that have built and operated human spaceflight systems for decades. We’re excited to invest and expand around that— engineers, operators, and astronauts working together and moving quickly towards building a crew capsule.” Hélène Huby, founder and CEO of The Exploration Company, said in a blog post.

According to The Houston Chronicle, The Exploration Company has about 30 employees in the Houston area.

The company was founded in 2021 by Huby, a French rocket scientist, and has raised more than $350 million in venture capital. It operates out of Germany, France, Luxembourg, Spain and Italy, with offices in the U.S. and the United Arab Emirates. It is also developing a reusable, high-thrust rocket engine known as Storm.

UH lands $4M NIH grant to study early signs of autoimmune disease

NIH funding

The University of Houston recently received a $4 million National Institutes of Health grant to support a 10-year longitudinal study to identify the earliest biological markers of autoimmune disease.

Led by Chandra Mohan, the Hugh Roy and Lillie Cranz Cullen Endowed Professor of Biomedical Engineering, the study aims to examine what causes Systemic Autoimmune Rheumatic Diseases (SARDs) and to identify targets for future treatments. The study will be carried out in collaboration with Dr. Karen Costenbader at Harvard Medical School, Boston.

SARDs include conditions like rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and systemic sclerosis—all are considered chronic diseases currently without a cure. Autoimmune diseases affect over 30 million people globally, according to UH.

SARDs occur when the body’s immune system attacks healthy, non-threatening tissues and organs. According to UH, in these diseases, the body often attacks nuclear antigens, creating anti-nuclear autoantibodies, which can be early detection signs for SARDs in more than 50 percent of patients, Mohan says.

Researchers will study blood samples and environmental exposure over the 10 years to better understand anti-nuclear autoantibodies.

“Collectively, these studies will help identify the genetic, environmental and cellular factors that are operative at the two steps of SARD development, namely the emergence of anti-nuclear autoantibodies and disease onset,” Mohan said in a news release. “ More importantly, these studies will highlight functional molecular pathways and mechanisms that may be operative at each step."

Mohan predicts that looking at SARDs’ shared characteristics, rather than each disease individually, could help identify more treatment methods.

“Individual SARDs have been examined in silos without an attempt to discern shared underlying features at the molecular level,” he added in the release. “Current understanding of the initial (and likely shared) origins of SARDs is only rudimentary but urgently needed to develop means for prevention and treatment.”

Earlier this year, UH also received an $11 million NIH grant to conduct a first-of-its-kind study of early language development in children ages 18 to 24 months. Read more here.